Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007251 | Influenza, Human NIH | 0.25 |
| D004630 | Emergencies NIH | 0.18 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study aims to quantify the inpatient and ER visits burden of laboratory-confirmed influenza, and compare the clinical features, severity, complications, risk factors and socioeconomic impact of influenza in children presenting with acute respiratory illness (ARI) and/or isolated fever, with or without laboratory-confirmed influenza.
Description: ARI was defined as one or more of the following symptoms: sore throat (in children greater than or equal to (≥) 3 years old), coryza (runny nose), cough, breathing difficulties. Isolated fever was defined as: oral temperature ≥37.5°C / axillary temperature ≥37.5°C / Rectal temperature ≥38°C / tympanic temperature on oral setting ≥37.5°C / tympanic temperature on rectal setting ≥38°C without an obvious cause.
Measure: Number of Subjects With Laboratory-confirmed Influenza Presenting With an Acute Respiratory Illness (ARI) and/or Isolated Fever Time: Day 0 till Day 28-37Description: Ward specific room charge and Intensive Care Unit (ICU) were computed as daily charge multiplied by the number of days.
Measure: Direct Medical Cost Per Hospitalization or ER Visit With Laboratory-confirmed Influenza Time: Day 0 till Day 28-37Description: Among the other laboratory-confirmed respiratory viruses there were:adenovirus, respiratory syncytial virus, parainfluenza virus 1, 2 and 3, metapneumovirus, bocavirus, rhinovirus or coronavirus. The outcome was assessed in subjects with an acute respiratory illness (ARI) and/or isolated fever episode.
Measure: Number of Subjects With Other Laboratory-confirmed Respiratory Viruses Time: Day 0 till Day 28-37Description: Deaths from ARI and/or fever episodes by laboratory-confirmed influenza status were assessed.
Measure: Number of Subjects With Fatal Outcomes Time: Day 0 till Day 28-37Description: The outcome assessed the various complications by laboratory-confirmed influenza status.
Measure: Number of Subjects With Secondary Bacterial Infections Time: Day 0 till Day 28-37Description: Risk factors were classified as pre-existing conditions, breast-feeding status and day-care status.
Measure: Number of Subjects With Potential Risk Factors at Study Start by Laboratory-confirmed Influenza Status Time: Day 0 till Day 28-37Description: The outcomes was assessed in subjects with laboratory-confirmed influenza status
Measure: Number of Days of Hospitalization Time: Day 0 till Day 28-37 (between October 2010 until May 2011)Description: ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.
Measure: Number of Subjects Using Any ARI and/or Fever Related Medication Taken Prior to Hospitalization or ER Visit by Laboratory-confirmed Influenza Status Time: Day 0 till Day 28-37Description: ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.
Measure: Number of Subjects Using Any ARI and/or Fever Related Medication Prescribed During Hospitalization or ER Visit by Laboratory-confirmed Influenza Status Time: Day 0 till Day 28-37Description: ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.
Measure: Number of Subjects Using Any ARI and/or Fever Related Medication Prescribed Since Hospitalization or ER Visit by Laboratory-confirmed Influenza Status Time: Day 0 till Day 28-37Description: ARI and/or fever related medication included: antivirals, antibiotics, cough suppressants, pain medication, antipyretics and mucolytics.
Measure: Number of Subjects Using Any Non-prescribed ARI and/or Fever Related Medication Taken Since Hospitalization or ER Visit Time: Day 0 till Day 28-37Description: School absenteeism was assessed among patients during the follow-up period by laboratory-confirmed influenza status.
Measure: Number of Days of School Absenteeism Time: Day 0 till Day 28-37Description: This outcome assessed absenteeism among caregivers to provide patient care during the follow-up period by laboratory-confirmed influenza status.
Measure: Number of Days of Parent or Caregiver Time Off Work Time: Day 0 till Day 28-37Description: This outcome assessed the number of cases with household contacts presenting influenza like illness symptoms during the follow-up period by laboratory-confirmed influenza status.
Measure: Number of Subjects With Household Members With Influenza-like Illness Time: Day 0 till Day 28-37Description: This outcome assessed the proportion of influenza like illness (ILI) among household members of children < 15 years with and without laboratory-confirmed influenza.
Measure: Proportion of Household Members Presenting Influenza Like Illness Symptoms (ARI and/or Isolated Fever) Time: Day 0 till Day 28-37Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports